Oruka Therapeutics, Inc. (ORKA)
NASDAQ:ORKA
Want to see ORKA full AI Analyst Report?
Total Valuation
Oruka Therapeutics has a market cap or net worth of $3.66B. The enterprise value is $2.22B.
Market Cap$3.66B
Enterprise Value$2.22B
Share Statistics
Oruka Therapeutics has 60,312,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding60,312,100
Owned by Insiders8.33%
Owned by Institutions48.75%
Financial Efficiency
Oruka Therapeutics’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is -25.76%.
Return on Equity (ROE)-0.22
Return on Assets (ROA)-0.22
Return on Invested Capital (ROIC)-25.76%
Return on Capital Employed (ROCE)-0.26
Revenue Per Employee0.00
Profits Per Employee-3.77M
Employee Count28
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Oruka Therapeutics is ―. Oruka Therapeutics’s PEG ratio is 0.24.
PE Ratio―
PS Ratio0.00
PB Ratio2.93
Price to Fair Value2.93
Price to FCF-15.64
Price to Operating Cash Flow-36.78
PEG Ratio0.24
Income Statement
In the last 12 months, Oruka Therapeutics had revenue of 0.00 and earned -105.43M in profits. Earnings per share was -2.31.
Revenue0.00
Gross Profit-83.00K
Operating Income-122.05M
Pretax Income-105.43M
Net Income-105.43M
EBITDA-121.97M
Earnings Per Share (EPS)-2.31
Cash Flow
In the last 12 months, operating cash flow was -90.92M and capital expenditures -269.00K, giving a free cash flow of -91.19M billion.
Operating Cash Flow-90.92M
Free Cash Flow-91.19M
Free Cash Flow per Share-1.51
Dividends & Yields
Oruka Therapeutics pays an annual dividend of $19.356, resulting in a dividend yield of ―
Dividend Per Share$19.356
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.19
52-Week Price Change453.52%
50-Day Moving Average58.60
200-Day Moving Average34.33
Relative Strength Index (RSI)47.51
Average Volume (3m)2.08M
Important Dates
Oruka Therapeutics upcoming earnings date is Aug 17, 2026, TBA (Confirmed).
Last Earnings DateMay 13, 2026
Next Earnings DateAug 17, 2026
Ex-Dividend Date―
Financial Position
Oruka Therapeutics as a current ratio of 22.37, with Debt / Equity ratio of 0.37%
Current Ratio22.37
Quick Ratio22.37
Debt to Market Cap<0.01
Net Debt to EBITDA0.37
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Oruka Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Oruka Therapeutics EV to EBITDA ratio is -10.97, with an EV/FCF ratio of -15.13.
EV to Sales0.00
EV to EBITDA-10.97
EV to Free Cash Flow-15.13
EV to Operating Cash Flow-15.16
Balance Sheet
Oruka Therapeutics has $388.83M in cash and marketable securities with $1.81M in debt, giving a net cash position of $387.02M billion.
Cash & Marketable Securities$388.83M
Total Debt$1.81M
Net Cash$387.02M
Net Cash Per Share$6.42
Tangible Book Value Per Share$10.35
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Oruka Therapeutics is $137.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$137.25
Price Target Upside99.14% Upside
Analyst ConsensusStrong Buy
Analyst Count13
Revenue Growth Forecast―
EPS Growth Forecast54.61%